Abstracts 2023
Oral Presentations (40)
- P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.
- P002 Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitis
- P003 MicroRNAs as biomarkers in Inflammatory Bowel Disease unclassified (IBDU) patient samples may predict the development from IBDU to Crohn’s Disease or Ulcerative Colitis
- P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare
- P005 Molecular-based classification of ulcerative colitis and its dynamic
- P006 Engineered propionate-producing bacteria attenuates murine colitis by modulating the immune function of resident macrophages via histone deacetylase
- P007 Paradoxical effects of high and low emulsifier diets on intestinal permeability in unstressed and stressed states in healthy human adults: a pilot randomised controlled feeding trial.
- P008 Fibrostricturing Crohn’s disease is characterised by an imbalance in active eosinophils, Th1, Th2 and regulatory T cells
- P009 IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells
- P011 Patient-derived organoids as an epithelial model for preclinical IBD research and drug development.
- P012 The administration of mm-miR-378a-3p exacerbates chronic inflammation and fibrosis in a murine intestinal model
- P013 Role of IL-36RA mutations in Crohn’s disease
- P014 Behaviour in mice with chronic DSS colitis mimics fatigue in IBD and is associated with neuroinflammation
- P015 CITE-seq analysis revealed immune cell diversity in colonic mesenteric lymph nodes from IBD patients
- P016 Dietary supplementation with Brazilian jaboticaba-sabará fruit (Myrciaria jaboticaba (Vell.) O. Berg) ameliorates colitis-driven colorectal cancer in mice
- P017 Fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum
- P018 Expression of annexin A1 and NLRP3 inflamassome in Chron's disease
- P019 Host-Enterobacteriaceae interactions and mitochondrial dysfunction in Crohn’s colitis
- P020 Characterisation of mucus in patients with Crohn’s disease
- P021 Microbial metabolite receptors as mediators of pathogenic processes in Inflammatory Bowel Disease.
- P022 A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease
- P023 Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence.
- P024 Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease
- P025 Colonic rather than ileal expression of ITGA4/ITGB7 correlates with local intestinal inflammation in IBD
- P026 Cost per Response/Remission analysis of biologic therapies availables in Argentina for the treatment of Bio-exposed patients with moderate-to-severe active Ulcerative Colitis
- P027 Anorectal Motility Disorders in Inflammatory Bowel Disease patients
- P028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?
- P029 Histopathological characterization of a chronic DSS-induced mouse model of IBD with intestinal fibrosis
- P030 Assessing dietetic interventions in inflammatory bowel disease patients
- P031 CKD-506, a new histone deacetylase 6 inhibitor, suppresses immune cells and restores intestinal epithelial function
- P032 Distinct immune cell trigger responses in Ulcerative Colitis – Results from an in vivo human intestinal injury model
- P033 The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study.
- P034 A common IL2RA polymorphism alters natural killer cell immunophenotype and function in Crohn’s disease, with implications for IL-2 based therapy
- P035 Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBD
- P036 Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles
- P037 Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease
- P038 Notch pathway in fibrosis: a new anti-fibrotic therapy in Crohn's disease?
- P039 The disappearance of cell death brakes in inflammatory bowel disease: a step towards molecular healing
- P040 Caspase-8 blockade attenuates NSAID-induced colitis and cell death via NLRP3 inflammasome and NF-κB activation
- P041 The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on it
- P042 Distinct gene expression profile associated to inflammation and neoplastic progression in longstanding ulcerative colitis
- P043 ALI culture derived from human organoids recapitulates cell composition during intestinal crypt formation
- P044 Ex vivo effects of infliximab on the long non-coding RNAs expression levels in Crohn´s disease
- P045 Local administration of extracellular vesicles from adipose-derived stromal cells promote healing in a rat model of radiation colitis – a pilot study
- P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity
- P047 Osteopontin in colitis-associated carcinoma (CAC)
- P048 Deep phenotyping of the peripheral immune cell compartment in Crohn‘s Disease
- P049 Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease
- P050 Intraperitoneally injected 3-dimensional cultured tonsil-derived mesenchymal stem cells in murine colitis model form aggregates with mouse immune cells: A preliminary study
- P051 Immune phenotypes in acute severe ulcerative colitis
- P052 IL-12p70 as a potential driver of pathogenic IL-17+IFNγ+ mucosal memory TIGITneg T cells in a subgroup of severe CD patients
- P053 Ustekinumab decreases circulating Th1, Th17, and MAIT cells in Crohn’s disease
- P054 Secreted inflammatory protein profiles following treatment of ex-vivo human inflammatory bowel disease explants with licenced biologic therapies
- P055 Exosomal miR-103a-3p from Crohn’s creeping fat-derived ASCs contributes to intestinal fibrosis by targeting TGFBR3 and activating fibroblasts
- P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring C
- P057 Development and evaluation of the i-Tracker Certolizumab and i-Tracker Anti-Certolizumab kits: rapid and innovative tests intended for monitoring patients treated with Certolizumab.
- P058 Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients
- P059 Klebicin as a novel therapy for Klebsiella infection management
- P060 Restoration of occludin and claudin-1 expression in patients with Crohn’s disease receiving anti-TNF treatment.
- P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes
- P062 Antibody responses to SARS-CoV-2 vaccination outperform responses induced by natural infection in patients with IBD receiving immunosuppressive medications: a report from the ICARUS-IBD consortium.
- P063 Host-mycobiome interactions during the resolution of inflammation in experimental colitis
- P064 High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response.
- P065 Altered B cell expansion and maturation in Crohn’s disease
- P066 ON104, a novel bioengineered antibody targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) shows efficacy in two distinct models of experimental colitis
- P067 Fractal analysis of extracellular matrix as a new histological method for observer-independent quantification of intestinal fibrosis in Crohn’s Disease
- P068 Polyunsaturated fatty acid excess fuels pro-inflammatory transcriptional networks in GPX4 deficient intestinal epithelial cells
- P069 Elevated adaptive immune responses to multiple Lachnospiraceae bacterial flagellins in therapy-naïve pediatric CD patients are associated with distinct immune pathology.
- P070 Global cytokine—cytokine interaction framework to uncover communication channels between elements of the immune system
- P071 T-cell, B-cell and monocytic infiltrations of myenteric plexus in IBD
- P072 : Circadian misalignment by simulated night shifts decreases colonoid barrier integrity in Ulcerative Colitis
- P073 Let´s talk about sex: an unicentric cross-sectional study on sexual dysfunction, sexual satisfaction and body schema disorders in Inflammatory Bowel Disease
- P074 Interferon-γ promotes antigen processing and presentation pathway in the intestinal epithelium of patients with Crohn’s disease
- P075 Characterisation and structural analysis of a new murine model to study postoperative fibrotic recurrence in Crohn’s disease combining ileocecal resection with chronic colitis
- P076 Abdominal pain severity for IBD in remission correlates with genetic clustering and enzymatic activity of faeces-derived Candida albicans strains
- P077 Group 1 innate lymphoid cells in creeping fat of Crohn’s disease
- P078 Physiological hypoxia improves growth and functional differentiation of human intestinal epithelial organoids.
- P079 Attenuation of inflammation and histologic production-dependent improvement by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitis
- P080 Mucosal clock and inflammation regulatory genes are disrupted in treatment naïve pediatric patients with ulcerative colitis
- P081 The application of multiomics to investigate the evolution of inflammatory bowel disease in pediatric and adult patients
- P082 The CCR9/CCL25 axis is specific to the ileum and is correlated with stricturing disease
- P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis
- P084 Response to appendectomy in refractory Ulcerative Colitis appears based on two distinct inflammatory phenotypes
- P085 Gut microbiota profile changes in patients with Ulcerative Colitis
- P086 Sirtuin 7 inhibitor attenuates colonic mucosal immune activation in mice–potential therapeutic target in Inflammatory Bowel Disease
- P087 Calcitonin gene related peptide beta (CGRPβ): a new player in inflammatory bowel disease pathophysiology
- P088 Restoration of gut microbiota and changes in inflammatory susceptibility by dextran sulfate sodium after antibiotic treatment in mice
- P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis
- P090 Low-density neutrophils are higher in individuals with active ulcerative colitis
- P091 Gender focused investigation of sexual dysfunction, sexual satisfaction and body schema disorders in male and female patients with Inflammatory Bowel Disease
- P092 Punica Granatum affects gut biofilm-forming bacteria and promotes intestinal mucosal healing regulating the crosstalk between epithelial cells and intestinal fibroblasts
- P093 Creeping fat-derived long chain free fatty acids drive intestinal muscularis propria muscle cell proliferation via carnitine palmitoyltransferase 1 (CPT-1) – a relevant mechanism for stricturing Crohn’s disease
- P094 Impacts of 5-aminosalicylic acid on the intestinal microbiota leading to the anti-inflammatory effect
- P095 Newly discovered gut matrikines from Crohn’s disease intestinal tissue induce cell proliferation, activation and inflammatory response in intestinal myofibroblasts in vitro
- P096 Characterization of suppressive immune cell subsets in mouse models of colitis-associated colorectal cancer
- P097 Various regulatory single nucleotide polymorphisms regulate similar biological pathways in Crohn’s disease
- P098 Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action
- P099 IL-33 activates CD73-expressing cells promoting tumorigenesis during colitis-associated colorectal cancer
- P100 Atypical Anti-Neutrophil Cytoplasmatic Antibodies Are Antibodies Against Neutrophil Extracellular Traps: A Novel Pathophysiological Mechanism In Ulcerative Colitis
- P101 Circulating MicroRNA-16 in Inflammatory Bowel Disease Patients - Potential Biomarker to Assess Inflammation
- P102 A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease
- P103 Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation
- P104 Exploring the transcriptomic miRNA signatures of Egyptian Inflammatory Bowel Disease patients
- P105 Epithelial microRNA signatures as potential biomarkers in Crohn’s disease related to clinical and endoscopic activity
- P106 Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach
- P107 Decreased epithelial keratinization contributes to defective wound healing in Crohn's disease fistula
- P108 Development and evaluation of the i-Tracker Risankizumab and i-Tracker Anti-Risankizumab kits: rapid and innovative tests intended for monitoring patients treated with Risankizumab.
- P109 Using baseline Peripheral blood mononuclear cell (PBMC) transcriptomics of Crohn Disease patients receiving Ustekinumab treatment as a tool to assess potential response at 1 year
- P110 Fibroblast activation protein is strongly expressed in intestinal fibrosis in inflammatory bowel disease patients
- P111 Efficacy of a novel long-acting lipidated interleukin-22, alone and in combination with anti-TNF treatment, in a murine chronic DSS colitis model
- P112 S1PR expression on circulating immune cells is not limited to lymphocytes in patients with inflammatory bowel disease
- P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model
- P114 Increased serum levels of the migraine biomarker calcitonin gene related peptide alpha in a newly diagnosed inflammatory bowel disease population: a new mediator for the gut-brain-axis
- P115 Trehalose modulates Dextran Sulfate Sodium-induced colitis by regulating macrophage polarization
- P116 RIPK3 - a new marker for assessment of ulcerative colitis severity
- P117 Low-Intensity Pulsed Ultrasound as a new approach of gut disruptive liquid biopsy to boost the release of mucosal extracellular vesicles in Ulcerative Colitis
- P118 Induction of ETS1 and senescence associated secretory phenotype in human intestinal fibroblasts
- P119 Perianal Crohn’s disease and the development of colorectal and anal cancer: A systematic review and meta-analysis
- P120 Development and validation of a dedicated score to assess transmural response and transmural healing in patients with Crohn’s disease : final results of the DEVISE-CD project
- P121 Clinicomic profiles new feature patterns based on a simplified location classification for Crohn’s disease
- P122 External validation of the Picasso Histological Remission Index (PHRI) to assess endoscopic and histological remission and predict long-term outcome in Ulcerative Colitis: A multicentre prospective study.
- P123 Development of an end-to-end Mayo endoscopic score machine learning algorithm for use in clinical trials of ulcerative colitis
- P124 Risk of surgery in inflammatory bowel disease: A systematic review and meta-analysis of sex-based differences
- P125 LCI/BLI chromoendoscopy plus CAD-EYE artificial intelligence for the detection and characterization of endoscopic visible lesions in ulcerative colitis
- P126 Ask twice: The importance of repeated faecal calprotectin testing prior diagnostic colonoscopy in an adult inception cohort.
- P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years
- P128 The role of small bowel capsule endoscopy as a diagnostic tool in isolated complex perianal disease
- P129 Intestinal ultrasound at week 12 predicts long-term endoscopic response to biologics in ulcerative colitis
- P130 Intestinal ultrasound combined to fecal calprotectin is effective to predict endoscopic mucosal healing in ulcerative colitis: a cross-sectional study
- P131 Is stress associated with subclinical inflammation in Ulcerative Colitis? A population-based cross-sectional cohort study in southeastern Sweden
- P132 Prognosis and molecular characteristics of IBD-associated colorectal cancer: experience from a French tertiary-care center
- P133 Risk Factors for the Occurrence and Severity of Vertebral Fractures in Inflammatory Bowel Disease Patients: A Nationwide Population-Based Cohort Study
- P134 Pediatric granulomatous appendicitis, how can it be precursor of Crohn Disease?
- P135 Atopic dermatitis is associated with the clinical course of inflammatory bowel disease
- P136 Multidimensional assessment of visceral hypervigilance in patients with IBD
- P137 The prevalence and severity of sexual dysfunction in male IBD patients: an observational single-center study
- P138 The use of video capsule endoscopy (vce) in patinets with a new diagnosis of Crohn's disease: the experience of one center
- P139 Inflammatory bowel disease and impairment of working life
- P140 Costs of home-monitoring by telemedicine versus standard care management of Inflammatory Bowel Disease – a Danish register-based five-year follow-up study
- P141 Risk Factors of Atherosclerotic Cardiovascular Disease (Ischemic Heart Disease and Cerebrovascular Accident) in Patients With Inflammatory Bowel Disease: a hospital-based cohort
- P142 Evaluation of quantitative phase imaging for automated assessment of histopathological remission in patients with Ulcerative Colitis
- P143 Outcomes of ulcerative colitis-associated dysplasia patients treated with endoscopic submucosal dissection: An extended analysis of a single center cohort
- P144 Impact of major medication discontinuation during the first wave of COVID-19 pandemic on the risk of early relapse in patients with inflammatory bowel disease: a French observational retrospective study
- P145 Phenotypic progression of Crohn’s disease : assessment of risk factors in a Tunisian population
- P146 Stigmatization and resilience in inflammatory bowel disease patients at one-year follow-up
- P147 Trends in choice of first line biologic therapy for patients with Inflammatory Bowel Disease. An observational cohort study.
- P148 Work Ability Index (WAI) as a suitable instrument to assess work ability among IBD patients
- P149 Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result
- P150 Identification of features associated with poor outcomes in pediatric patients with ulcerative proctitis: A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN
- P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations
- P152 The prevalence of Thiopurine-methyltransferase and NUTD15 in patient with ulcerative colitis: a hospital-based study in central Taiwan
- P153 Association between ustekinumab trough concentrations and clinical, biochemical, and endoscopic outcomes in patients with Inflammatory Bowel Disease
- P154 A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts
- P155 Natural history of anal stricture in pediatric-onset Crohn’s disease: a two-decades population-based study
- P156 Submucosa hypertrophy of active UC patients suggests transmural involvement in UC-associated inflammation
- P157 Serial daily recording of patient-reported outcomes (PRO2) might predict treatment change in the patients with Ulcerative Colitis.
- P158 Intestinal Ultrasound at IBD diagnosis predicts surgery – a Copenhagen IBD cohort study
- P159 Development of a core set of quality of care measurements for patients with inflammatory bowel disease in Belgium
- P160 Influence of sarcopenia on perioperative management and postoperative outcome in patients with Crohn’s Disease undergoing intestinal surgery: a retrospective study
- P161 Simplified Endoscopic Mucosal Assessment for Crohn’s Disease (SEMA-CD): External Application and Prognostic Value Definition.
- P162 Earlier (luminal) surgery is associated to reduced postoperative morbidity in ileocaecal Crohn’s disease: results from SURGICROHN – LATAM study.
- P163 Is Peri-appendiceal Inflammation of Clinical Significance in Patients with Ulcerative Colitis?
- P164 Dysplasia detection rates in a surveillance program real-world data from a tertiary referral center for inflammatory bowel diseases
- P165 Vitamin D deficiency is associated with poor sleep quality in patients with Crohn’s disease
- P166 Calprotectin in patients with perianal fistula: the CANALS study
- P167 Ileocecal valve that cannot be intubated during colonoscopy in patients with Crohn’s disease: Is this a sign of poor prognosis?
- P168 Development of predictive model for early detection of Inflammatory Bowel Disease in Korea
- P169 Copy number variation of alpha defensin 1-3 is a predictive marker of therapeutic response in ulcerative colitis
- P170 Can histological activity of ulcerative colitis be predicted by assessment of the rectosigmoid colon?
- P171 Subfertility in young patients with Crohn´s disease. A case-control study.
- P172 Metabolic disorders with non-alcoholic fatty liver disease in people with inflammatory bowel disease
- P173 Patency capsule: A novel independent predictor for long-term outcomes among patients with quiescent Crohn’s disease
- P174 Uncontrolled depression and female gender increase the risk of severe fatigue in patients with inflammatory bowel disease under infliximab therapy.
- P175 Burden of Inflammatory Bowel Disease in Mexico: RISE-MX, a Multi-center, Retrospective, 3-Year Data Study
- P176 Clinical features of acute severe ulcerative colitis according to steroid dependency: A KASID multicenter study
- P177 C-reactive protein/albumin ratio: a novel biomarker for monitoring of the disease activity in Ulcerative Colitis patients
- P178 Evaluation of the Ulcerative Colitis Intestinal Ultrasound (UC-IUS) Index in Pediatric patients with newly diagnosed ulcerative colitis
- P179 Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
- P180 Ileorectal anastomosis preserves female fertility after colectomy in Ulcerative Colitis
- P181 infliximab exposure during induction associate with time to remission and disease control of inflammatory bowel disease
- P182 Modified Multiplier SES-CD (MM-SES-CD) and laboratorial Crohn’s disease activity parameters: is there any association?
- P183 Development of a new simple ultrasound activity score for intestinal Behçet's Disease
- P184 Identification of the PAI-1, as a potential non-invasive, fecal biomarker in the Inflammatory Bowel Diseases
- P185 Global perception of normal life by healthcare professionals and IBD patients: mind the gap
- P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies
- P187 Intestinal ultrasound is accurate for detecting intra-abdominal complications in Crohn’s disease: a meta-analysis
- P188 Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn’s disease
- P189 Prospective Validation Study Regarding Disease Complications of the Toronto IBD Global Endoscopic Reporting (TIGER) Score in Ulcerative Colitis and Crohn’s Disease Patients
- P190 Delayed IBD diagnosis leads to worse outcomes over years, with multiple implications on service delivery
- P191 Robotic Surgery shows significant promise in delivering superior outcomes for patients with Inflammatory Bowel Disease
- P192 Comparison of Endoscopic Scoring System and Simplified Magnetic Resonance Index of Activity in Patients with Small Bowel Crohn’s Disease: Basis for Therapeutic Plan?
- P193 Predicting the middle-term efficacy of molecular-targeted medications for Ulcerative Colitis based on the intestinal ultrasound findings
- P194 Characterization of Protein Disulfide Isomerases in adult and pediatric Crohn’s Disease and association with inflammation and fibrosis
- P195 Is fecal calprotectin truly valuable in the management of isolated small bowel Crohn’s disease?
- P196 Major variance in scoring of endoscopic recurrence after ileocolic resection for Crohns Disease – a systematic review and meta-analysis
- P197 A biomarker of early mucosal destruction: Neutrophil-mediated type IV collagen degradation is elevated in patients with Crohn’s Disease and Ulcerative Colitis
- P198 Sonographic features of colonic pseudopolyposis in inflammatory bowel diseases
- P199 Clonal patterns between pouch neoplasia and prior colorectal neoplasia in Inflammatory Bowel Disease patients: an exploratory cohort study
- P200 Hepatic Steatosis but not Fibrosis is independently associated with poor outcomes in patients with Inflammatory Bowel Disease
- P201 Assessment of factors associated with cumulative bowel damage in surgically naïve patients using Lemann index and global MaRIA index in Crohn’s disease
- P202 Accuracy of blood-PCR for diagnosing CMV Colitis in patients with Inflammatory Bowel Disease
- P203 Oral omeprazole and diclofenac intake is associated with increased faecal calprotectin levels: a randomised open-label clinical trial
- P204 Preoperative optimization of patients with inflammatory bowel disease: a multicentre study of EIGA Group
- P205 Impact of histologic disease activity on long-term outcomes in patients with ileal pouch-anal anastomosis for ulcerative colitis
- P206 Artificial Intelligence reproduces central reading for automated scoring of colonoscopies from multiple clinical trials in Ulcerative Colitis.
- P207 Colonic location at diagnosis of pediatric-onset Crohn’s disease is associated with a pejorative disease course: a two decades population-based study
- P208 Validation of the IBD-Disk in a Portuguese cohort of patients with inflammatory bowel disease
- P209 Delayed IBD diagnosis increases risk of requiring biologics in first 4-years - an Inception cohort study
- P210 Long-term outcome of very early onset inflammatory bowel disease associated with primary sclerosing cholangitis: a multicenter study from the Pediatric IBD Porto Group of ESPGHAN
- P211 Factors associated with estimated cardiorespiratory fitness in patients with Inflammatory Bowel Disease: an exploratory analysis of real-world data
- P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019
- P213 High prevalence and risk factors for nonalcoholic fatty liver disease in patients with Crohn's disease
- P214 Cine MRI assessment of colonic motility in patients with ulcerative colitis associated constipation.
- P215 Deep immune phenotyping of unconventional T cells reveals a depletion in Mucosa Associated T Cells (MAIT) in IBD patients with extraintestinal manifestations
- P216 Oral Budesonide and low serum albumin levels at surgery are associated with a higher risk of postoperative intra-abdominal septic complications after primary ileocecal resection for Crohn’s disease: a retrospective analysis of 853 consecutive patient
- P217 Volatile organic metabolites to predict clinical response to biological therapy in inflammatory bowel disease
- P218 It is time to grow up: readiness is associated with better outcomes in a prospective study of pediatric transition patients with Inflammatory Bowel Disease
- P219 Migraine Is Associated with the Development of Inflammatory Bowel Disease: A Nationwide, Population-Based Study
- P220 Patient’s disease perception and health-related quality of life with IBD: Results from a Spanish cohort with 15 years of follow up
- P221 Validity of the Self-administered Comorbidity Questionnaire in patients with Inflammatory Bowel Disease
- P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life
- P223 The usefulness of tissue calprotectin in pediatric Crohn’s disease – a pilot study.
- P224 Diagnostic delay in inflammatory bowel disease is not associated with difficult access to healthcare facilities: a clinical study on incidental cases
- P225 The accuracy of different intestinal ultrasound parameters in detecting endoscopic activity in patients with inflammatory bowel disease
- P226 Dietary patterns differ in the newly diagnosed IBD cohort with ethnicity as a key confounding variable, a case control study
- P227 Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
- P228 Machine learning models utilizing simple laboratory tests may assess endoscopic activity in ulcerative colitis
- P229 Comparison of the characteristics of segmental mucosal microbiome according to the extent of inflammation in ulcerative colitis.
- P230 Adalimumab in Crohn’s disease is protective against periodontitis based on a validated oral health questionnaire
- P231 Impact of age of Inflammatory Bowel Disease diagnosis on disease phenotype and severity in elderly patients
- P232 Serum neutrophil gelatinase associated lipocalin (NGAL) as a marker of activity of Inflammatory Bowel Disease
- P233 Malnutrition diagnosis based on the GLIM criteria and patients’ dietary beliefs and practices impact negatively the quality of life of IBD patients
- P234 Differentiation of histopathological features between sporadic and colitis-associated colorectal cancer in a nationwide large cohort.
- P235 Patients with inflammatory ileal pouch anal anastomosis (IPAA) disorders are characterized by a distinct breath volatile organic compounds (VOC) metabolome profile
- P236 Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn’s Disease: The Challenges of Accurate Endoscopic Scoring
- P237 Superior predictive value of intestinal ultrasound over endoscopic severity for colectomy risk in patients with ulcerative colitis
- P238 The ‘Malnutrition Universal Screening Tool’ (MUST) is less effective than an IBD specific Malnutrition Inflammation Risk Tool (MIRT) in identifying malnutrition risk with hospital admissions and surgical complication
- P239 Incidence of Long COVID and impact of medications on the risk of developing Long COVID in a nationwide cohort of Inflammatory Bowel Disease patients
- P240 Low surgery rates first year after diagnosis in Crohn’s disease; results from a large population-based inception cohort - the IBSEN III study
- P241 Gastrointestinal ultrasonography diagnostic performance and feasibility in IBD during pregnancy: a systematic review and narrative synthesis.
- P242 Universal exclusion of patients with Permanent Ileostomy in Crohn’s disease clinical trials: A systematic review
- P243 The association between serological markers ASCA and ANCA and response to induction treatment in therapy-naïve children with inflammatory bowel disease: an international prospective study
- P244 Prognostic Value of post-biological induction fecal calprotectin concentration on the long-term outcomes of Crohn’s disease
- P245 The Relationship Between the Endoscopic Healing Index and Magnetic Resonance Enterography In Crohn’s Disease Patients
- P246 2D Shear Wave Elastography as novel tool for the assessment of disease severity in patients with IBD
- P247 Oncostatin M and its receptor are markers of endoscopic and histological disease activity in Inflammatory Bowel Disease
- P248 The diagnostic accuracy of Intestinal ultrasound for assessing disease activity in the proximal ileum and jejunum in children with Crohn’s disease: Preliminary results of a prospective study
- P249 Colonic Explant Lactate Concentration and Disease Progression in Ulcerative Colitis
- P250 The impact of Primary Sclerosing Cholangitis (PSC) on fecal calprotectin assessment in individuals with Inflammatory Bowel Disease (IBD)
- P251 Level of Interleukin-17 in Inflammatory Bowel Disease and Its relation to disease activity.
- P252 Solid organ transplant (with the exception of liver) in patients with inflammatory bowel disease: An ECCO CONFER Multicentre Case Series
- P253 Histological Remission and Activity as Predictor of Relapse, Hospitalization, and Surgery in Ulcerative Colitis: Systematic Review and Meta-analysis
- P254 Deep Learning Model for Distinguishing MES 0 and MES 1 in Patients with Ulcerative Colitis
- P255 Diagnostic delay and economic burden in Inflammatory Bowel Disease: a single-centre experience in patients treated with biologics
- P256 Urinary lithogenic profile and gut and urinary microbiota in patients with inflammatory bowel diseases
- P257 Is colorectal screening in IBD fit for purpose?
- P258 The association between dietary quality and disease severity in Korean young adult patients with Crohn’s disease: A pilot study
- P259 Correlation between the Mayo endoscopic scoring system for Ulcerative Colitis with histological and clinical outcomes
- P260 Care pathway modelling and economic analysis of a single NHS IBD Service following introduction of Small bowel ultrasound.
- P261 Rate of Community Acquired Pneumonia, related hospitalization, and mortality among younger unvaccinated Inflammatory Bowel Disease patients
- P262 Development and validation of a score predicting non-response to intravenous corticosteroids in patients with Acute Severe Ulcerative Colitis on day 3 of admission
- P263 Raman spectroscopy analysis of saliva combined with an artificial neural network algorithm could discriminate between Ulcerative Colitis and Crohn’s disease
- P264 Machine learning can accurately predict development of Inflammatory Bowel Disease
- P265 Evaluation of the quality-of-care parameters in patients with inflammatory bowel disease in Brazilian hospitals
- P266 Potential oral microbial markers for differential diagnosis of Crohn’s disease and ulcerative colitis using machine learning model
- P267 Real-world artificial intelligence-aided colonoscopy does not improve adenoma detection rates in patients with Inflammatory Bowel Disease
- P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index.
- P269 Predicting IBD years before diagnosis using routine blood tests
- P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease
- P271 Variability in histologic activity of paired same-segment biopsies in Crohn’s disease dictates multiple biopsies needed to accurately evaluate histological status
- P272 Reduced delay in diagnosis of Crohn’s disease in patients presenting with perianal disease: results of a retrospective cohort study at a non-academic, IBD-expert centre in the Netherlands
- P273 Severity of colitis and clinical outcomes for patients admitted with acute UC in 2 large UK centres
- P274 Clinical manifestations, risk factors and prognostic factors of Cytomegalovirus Colitis in Inflammatory Bowel Disease patients
- P275 Anastomotic technique drives endoscopic recurrence in Postoperative Crohn's Disease: a systematic review and meta-analysis
- P276 Development and validation of a computed tomography-based radiomic nomogram to predict early-onset surgery risk in patients with Crohn’s disease
- P277 Predicting disease relevant features in Crohn’s Disease and Ulcerative Colitis from Haematoxylin & Eosin stained whole slide images using self-supervised deep learning
- P278 Endoscopic scoring system utilization for Inflammatory Bowel Disease activity assessment: a multicenter real-world evidence study from Argentina (DARE study)
- P279 Ileo-caecal stenosis in Crohn's disease: correlation between imaging, biology and endoscopy : preliminary results of a prospective study
- P280 Quality of life in military patients with Inflammatory Bowel Disease
- P281 Conversion of the ileal pouch-anal anastomosis to a continent ileostomy – outcome and patient satisfaction
- P282 Isolated colonic Crohn’s disease and extensive ulcerative colitis: is there a reel difference?
- P283 Awareness and perceptions of colorectal cancer risk and screening in Inflammatory Bowel Disease
- P284 Assessing Patient Experience in an Inflammatory Bowel Disease service. Can we measure an effect from socioeconomic deprivation – experience from the AWARE-IBD programme?
- P285 Correlation between the endoscopic scoring system SES-CD for Crohn’s disease with histological and clinical outcomes
- P286 Combined F18-FDG-PET-MRI-imaging: A promising tool for diagnostics of small bowel Crohn’s disease
- P287 Clinical characteristics and outcomes of ileal pouch–anal anastomosis (IPAA) inflammation in a Latin American (LA) IBD reference Center (I.
- P288 Application of a new classification of Fistulizing Perianal Crohn's Disease (FPCD) in clinical practice: evaluating the correlation between clinician and patient’s assessments and FPCD patient´s quality of life
- P289 Hyperoxaluria in patients after ileocolic resection
- P290 Development of an artificial intelligence model using stool pictures for predicting endoscopic mucosal inflammation in patients with Ulcerative Colitis; KASID multicenter study
- P291 Long term outcomes of children with ulcerative colitis after acute severe colitis: a multicenter study from the GETAID pédiatrique group
- P292 Complications in elderly-onset Inflammatory Bowel Diseases – A population-based study from the epidemiological database of the Israeli IBD Research Nucleus (Epi-IIRN)
- P293 Correlation between clinical measures to capture disease burden and prediction of the initial course of Crohn’s disease - findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
- P294 Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-based Study
- P295 Hocus Pocus: The Role Of Hand-Held Ultrasonography In Predicting Disease Extension And Endoscopic Activity In Ulcerative Colitis
- P296 MAGNIFI-CD index is appropriate for treatment monitoring in perianal Crohn’s Disease
- P297 The Toronto IBD Global Endoscopic Reporting (TIGER) Score and its Ability to Predict Outcomes Regarding Steroid and Biologic Use in Ulcerative Colitis and Crohn’s Disease Patients – A Construct Validation Study
- P298 Risk factors for the progression of non-alcoholic fatty liver disease in people with inflammatory bowel disease
- P299 Disability in newly diagnosed patients with Crohn´s Disease: initial results from the prospective CROCO (Crohn´s Disease Cohort) Study
- P300 Overweight and obesity in Inflammatory Bowel disease: epidemiology, disease course and treatment outcomes
- P301 Outcomes following colectomy for patients with Ulcerative Colitis, ten years of data from a tertiary referral centre
- P302 Precision medicine for a case with monogenic inflammatory bowel disease
- P303 Ultrasound is effective to identify mucosal healing in Crohn's disease patients : results of a cross-sectional study
- P304 Leucine-rich alpha 2 glycoprotein reduces the necessity for endoscopic examination for activity evaluation
- P305 Normal reference ranges and cut-off values for considering and performing endoscopy using the Sentinel CaliaGold® Calprotectin assay
- P306 Serum tryptophan metabolites as a biomarker for disease severity in patients with IBD
- P307 High frequency of Deep Infiltrating Endometriosis in patients with Inflammatory Bowel Disease: a nested case-control study
- P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study
- P309 Accuracy of PanMayo endoscopic score in predicting long-term disease outcomes in ulcerative colitis– a promising scoring system
- P310 Smoking is not an independent risk factor for surgery in patients with Crohn’s Disease on biologic therapy
- P311 Reliability of computed tomography enterography for evaluation of stricturing Crohn’s disease: Development of a Crohn’s disease stricture index
- P312 Retrospective study using ultrasonography in predicting clinical relapse of Crohn's disease
- P313 Understanding Inflammatory Bowel Disease patients’ experiences, expectations, and insights in identifying and managing anxiety and depression.
- P314 Microscopic appendicitis in ulcerative colitis: Feasibility of ultrasonographic diagnosis
- P315 The characteristics and severity of pediatric ulcerative proctitis
- P316 Inflammatory Bowel Disease and malignancy: What are the predictors of malignancy in Inflammatory Bowel Disease?
- P317 Patient satisfaction in a joint fistula clinic at a tertiary Inflammatory Bowel Disease centre in the United Kingdom
- P318 Protein FingerPrint assays reflecting neutrophil activity, mucosal damage, and tissue fibrosis are surrogate biomarkers for mucosal healing in pediatric Crohn’s disease
- P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study
- P320 Confocal Laser Endomicroscopy to predict the efficacy of vedolizumab as first-line biotherapy in ulcerative colitis
- P321 Increased modified DUBLIN scores are associated with serious ulcerative colitis and treatment failure
- P322 Mycobiome signature in pediatric patients with Inflammatory Bowel Disease
- P323 The Rate of and Risk of Dysplasia in Long Standing Ulcerative Colitis Patients Among Middle-Eastern Population
- P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update
- P325 Proton pump inhibitors are associated with a disabling course of Crohn’s disease
- P326 PREFAB-study: PRediction tool for Early identification of patients at risk of Crohn's disease in perianal Fistulas and ABscesses: interim analysis of a prospective pilot study at a non-academic, IBD-expert centre in the Netherlands
- P327 Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group
- P328 Holistic well-being as Patient-reported outcomes (PROs) in translational IBD research: Prospective capture of CUCQ32 as study endpoints for mechanistic biomarker MUSIC/GIDAMPs study.
- P329 Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease
- P330 Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn’s disease
- P331 Risk Factors and Prediction Model for Fecal Incontinence in Patients with Crohn’s Disease: A Multicenter Study
- P332 External validation of intestinal ultrasound scores to detect endoscopic activity in children and adults with Crohn's disease: A prospective cohort study
- P333 Early intestinal ultrasound remission is associated with endoscopic healing after one year of infliximab therapy in Crohn’s disease: a multicentre prospective study
- P334 Respiratory Manifestations and Association Between Disease Activity in Patients with Inflammatory Bowel Disease in a Reference Center in Salvador, Bahia, Brazil.
- P335 Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU)
- P336 Endoscopic scores as predictors of treatment failure in Ulcerative Colitis
- P337 Developing Preliminary MRI-based Classifier for Perianal Fistulizing Crohn’s Disease by Using Deep Convolutional Neural Networks
- P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease
- P339 Zonulin concentration in patients with ulcerative colitis with and without COVID-19 infection
- P340 Issues on implementing treat-to-target approach in Asia Pacific, Middle East and Africa: Reality, gaps, and way forward -APMA IBD Coalition
- P341 Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study
- P342 Treatment experience of perianal fistulising Crohn’s disease: a systematic literature review
- P343 Eosinophilic inflammation as an indicator of the activity of the course of Inflammatory Bowel Diseases
- P344 Diverting ileostomy in Inflammatory Bowel Disease's surgery: the real clinical cost analysis
- P345 Capsule endoscopy in the diagnostic process of suspected Crohn's Disease
- P346 Influence of diagnostic delay on ulcerative colitis characteristics at disease onset
- P347 Practical recommendations for the collection of the patient-reported outcomes included in the Health Outcomes Observatory (H2O) core data set for patients with inflammatory bowel disease
- P348 Disease trajectories in ulcerative colitis: Early identification of patients with endoscopic remission at Week 52
- P349 Faecal Calprotectin in Ulcerative Colitis - Associations with Mucosal Inflammatory Activity and Disease Extent
- P350 Endoscopic sedation in IBD patients: a propensity score-matched retrospective study
- P351 Validation of anterior thigh ultrasound for screening of sarcopenia and elevated body fat in Inflammatory Bowel Disease
- P352 Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients
- P353 Ulcerative Colitis in the IBSEN III study: Frequent use of biologics and low colectomy rates first year of disease.
- P354 Application of the clinical decision support tool to predict treatment outcomes in Crohn’s Disease patients treated with vedolizumab subcutaneous formulation
- P355 Motility in small bowel strictures in Crohn’s Disease measured with cine-MRI
- P356 CRAB Score, An Indian Insight into in hospital and long-term Colectomy following Acute Severe Ulcerative Colitis (ASUC)
- P357 Intestinal ultrasound as a promising non-invasive monitoring tool in patients with Ulcerative Colitis
- P358 Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea
- P359 Evaluation of usability and performance of home fecal sampling using a dedicated device
- P360 Role of intestinal ultrasound scores in the diagnosis of post-operative recurrence in Crohn's disease
- P361 Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
- P362 Systematic review: Oncological outcomes of patients with Inflammatory Bowel Disease undergoing segmental colonic resections for colorectal cancer and dysplasia
- P363 Depression and anxiety in Clostridioides difficile infection compared with inflammatory bowel disease during the Covid-19 pandemic
- P364 Presence of malnutrition adversely affects short-term clinical outcomes in a sample of patients with Crohn's disease (CD)
- P365 Psoriasis in Inflammatory Bowel Disease: Comparison of Extraintestinal Manifestations and Effect of Anti-TNF Therapies
- P366 genomics analysis and differentiation of Crohn's Disease, Intestinal Tuberculosis and Primary Intestinal Iymphoma
- P367 Significant impact on health care utilization upon implementation of an electronic IBD care management program.
- P368 The presence of extra-intestinal manifestations is associated with poor prognosis in acute severe ulcerative colitis: A KASID multicenter study
- P369 Do teenager and adult onset Crohn´s disease patients have different outcomes? A Portuguese cohort study
- P370 Correlation of the IBD Disk with intestinal ultrasound in patients with inflammatory bowel disease
- P371 Assessment Of Postoperative Complications Following Ileocecal Resection In Crohn’s Disease From A Low-To-Middle Income Country
- P372 Endoscopic ultrasonography in the differential diagnosis of Ulcerative colitis and Crohn's disease.
- P373 An Unusual Occurrence of Right-sided Colonic Neuroendocrine Carcinoma in Ulcerative Colitis – A case report
- P374 Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation study
- P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study
- P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis
- P377 Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's disease
- P378 Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-utero
- P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
- P380 Changes in faecal microbiome and metabolome are more pronounced in Crohn’s disease patients who adhered to the CD-TREAT diet and responded by calprotectin.
- P381 Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease
- P382 Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's Disease
- P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.
- P384 A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn’s Disease: first results of a prospective cohort
- P385 Risk-benefit assessment of IBD drugs: a physicians and patients survey
- P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
- P387 Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
- P388 Shear wave elastography predicts short-term response to induction therapy in patients with Crohn’s disease
- P389 Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study.
- P390 Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapy
- P391 Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with mod
- P392 Risk factors for postoperative recurrence after ileocolic resection for Crohn’s Disease: long-term results from a population-based cohort.
- P393 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION
- P394 Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre study
- P395 Short-term clinical efficacy and safety of teduglutide for Crohn’s disease patients with short bowel syndrome
- P396 Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn’s Disease
- P397 Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)
- P398 Disease clearance: a potential target for management of patients with Ulcerative Colitis
- P399 Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?
- P400 Identifying Nutritional targets in Crohn’s disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission
- P401 Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis
- P402 A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn’s Disease
- P403 Therapeutic compliance in patients with chronic inflammatory bowel disease.
- P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
- P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
- P406 Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim Analysis
- P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience
- P409 Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation
- P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
- P411 Early ultrasound assessment predicts therapy response: an easy tool for clinical decision making
- P412 Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan
- P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial
- P414 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
- P415 Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study
- P416 The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.
- P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Stud
- P418 Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.
- P419 Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative Colitis
- P420 Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn’s Disease
- P421 Real-world effectiveness and safety of vedolizumab induction therapy for Crohn’s disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
- P422 Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
- P423 Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
- P424 Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
- P425 The utility of intestinal ultrasound to inform clinical decision making
- P426 Sex and sexuality in IBD - the pediatric gastroenterologists’ point of view
- P427 One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn’s Disease
- P428 Pharmacist led clinic in Inflammatory Bowel Disease
- P429 Patient skeletal muscle area and postoperative clinical recurrence in Crohn’s disease: a retrospective study
- P430 Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission
- P431 A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence
- P432 Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
- P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
- P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials
- P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study
- P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial
- P437 Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .
- P438 Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension
- P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease
- P440 Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis
- P441 Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational study
- P442 Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel Disease
- P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
- P444 A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessed
- P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis
- P446 The INTESTINE study: INtended TEmporary STomas In crohN’s diseasE
- P447 Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
- P448 Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn’s disease – an update from the TISKids study
- P449 Minimally invasive IPAA in UC: Preliminary results from a referral center
- P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort
- P451 Early infliximab trough levels in paediatric IBD patients predict sustained remission
- P452 Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort study
- P453 The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.
- P454 No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomy
- P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study
- P456 Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn's disease patients
- P457 Treatment duration of ustekinumab in patients with Crohn’s disease (CD) and psoriasis (PSO) – real-world evidence from German claims data
- P458 Low adherence to Mediterranean diet is associated with increased adipose tissue in patients with ulcerative colitis (UC) after pouch surgery: a cross sectional study
- P459 Hospitalization, use of biologics and surgery rates in inflammatory bowel diseases: a single-center comparative analysis between public and private healthcare systems in a tertiary unit from Latin America
- P460 Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn’s disease patients
- P461 Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis
- P462 Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
- P463 Crohn’s disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study
- P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis
- P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- P466 Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
- P467 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn’s disease - a nationwide cohort from the epi-IIRN
- P468 Association of uncontrolled disease with quality of life and healthcare resource utilisation in Ulcerative Colitis patients treated with advanced therapy in the United States
- P469 Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis
- P470 Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn’s disease.
- P471 A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis
- P472 Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective study
- P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn’s disease: Week 48 analyses from the phase 2 GALAXI 1 study
- P474 Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitis
- P475 Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective study
- P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme
- P477 Patient satisfaction and cost saving analysis of telemedicine in patients with inflammatory bowel disease.
- P478 Platelet-related indicators for predicting vedolizumab response in patients with Ulcerative Colitis
- P479 Reliability and responsiveness of histologic disease activity indices in Crohn’s Disease
- P480 Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.
- P481 Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.
- P482 The experiences of people with IBD and comorbid anxiety or depression and their views on an online intervention for people with long term conditions (COMPASS): A qualitative framework analysis
- P483 Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?
- P484 Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New Zealand
- P485 An Assessment Of A Guided Self-Help and Patient Initiated Review Pathway for Ulcerative Proctitis
- P486 Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery
- P487 Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management
- P488 Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients’ acceptance
- P489 Surgery for enterocutaneous fistula: the strongest predictor of postoperative mortality in Crohn’s disease patients
- P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
- P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease
- P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
- P493 QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
- P494 Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
- P495 Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study
- P496 Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy
- P497 Is early bowel resection better than medical therapy for ileocolonic Crohn’s disease? A systematic review and meta-analysis
- P498 Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumab
- P499 Exclusive enteral nutrition induces transmural healing in adults with active Crohn’s disease
- P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
- P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort
- P502 Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost
- P503 The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ
- P504 Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells
- P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study
- P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
- P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey
- P508 Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn’s disease patients
- P509 Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.
- P510 Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.
- P511 Evaluation of home faecal calprotectin testing to aid remote management and enhanced self-management of Inflammatory Bowel Disease.
- P512 The counts of white blood cells are not predictive for long-term remission under treatment with thiopurines: a three year Japanese multi-center retrospective cohort study.
- P513 Prospective study on patients’ satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease
- P514 Serum levels of Klotho in inflammatory bowel disease: an exploratory study
- P515 Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative
- P516 Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study
- P517 Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.
- P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
- P519 Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
- P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme
- P521 Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitis
- P522 Kono-S anastomosis reduces endoscopic and surgical post-operative recurrence in Crohn’s disease. The SuPREMe-CD Trial Update.
- P523 Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.
- P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study
- P525 Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis
- P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
- P527 Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis
- P528 Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients
- P529 Year-two follow-up results of an observational study conducted in Crohn’s disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting
- P530 The Burden on Cohabitants of Patients with Inflammatory Bowel Disease: A Cross-Sectional Study
- P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
- P532 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
- P533 Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis
- P534 Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN
- P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
- P536 Is there any association between fat body mass and bone mineral density in patients with Inflammatory Bowel Disease?
- P537 Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study.
- P538 Suboptimal disease control is common in patients with Crohn’s perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study
- P539 Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment
- P540 The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus survey
- P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
- P542 Short term efficacy, safety and thromboembolic risk of tofacitinib in moderate to severe Ulcerative Colitis
- P543 Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice – Results of a nationwide, prospective, multicenter study in Germany (MUCUS)
- P544 Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patients
- P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases
- P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
- P547 Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis
- P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies
- P549 One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
- P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
- P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.
- P552 Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients
- P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
- P554 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
- P555 Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases
- P556 Surgery in high-risk paediatric Crohn’s Disease treated with up-front anti-TNF agents and long-standing biologic therapy
- P557 Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study
- P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
- P559 SARS-CoV-2 vaccination does not increase the risk for flares in Inflammatory Bowel Disease patients
- P560 Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial
- P561 Risk of stoma formation in patients with Crohn’s perianal fistulas over a two decades period. A cohort study from a tertiary referral center.
- P562 Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center
- P563 Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)
- P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn’s disease – a meta-analysis
- P565 Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients
- P566 Colitis due to immunotherapy with anti-PD-1: a case series
- P567 How can we predict the development of antibodies to infliximab in Crohn’s disease?
- P568 Patients with ulcerative colitis after pouch surgery are at risk for low spinal bone mineral density: a cross sectional study
- P569 Can thiopurines prevent crohn’s disease endoscopic postoperative recurrence in at risk patients?
- P570 Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD Study
- P571 Frequency and risk factors of advanced neoplasia in Korean IBD patients with Low Grade Dysplasia in previous surveillance
- P572 Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes
- P573 Change in fatigue in patients with Ulcerative Colitis or Crohn’s disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients
- P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
- P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis
- P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials
- P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
- P580 Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience
- P581 Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn’s disease: European multicentre study with a propensity-score matched analysis
- P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial
- P583 Tofacitinib for acute severe ulcerative colitis: a systematic review
- P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis
- P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study
- P586 Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study
- P587 Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn’s disease – a systematic review.
- P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
- P589 Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapy
- P590 ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical Trial
- P591 Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel Disease
- P592 Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experience
- P593 Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
- P594 Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission
- P595 Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
- P596 Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study
- P597 Usefulness of histological monitoring in predicting relapse after de-escalation of thiopurines in Ulcerative Colitis
- P598 The utility of the “Low Anterior Resection Syndrome SCORE” in assessing the postoperative outcomes of patients undergoing restorative proctocolectomy with ileal pouch anal-anastomosis for Ulcerative Colitis
- P599 Similar efficacy of mesalazine in adult and elderly patients: post-hoc analysis of randomised non-inferiority trial of 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
- P600 Democratic deliberation to assess Veteran preferences for biosimilar medication switching for the treatment of Inflammatory Bowel Disease in a resource-conscious setting.
- P601 Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
- P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
- P603 Real-world Scottish experience of anti-TNF therapy in paediatric Crohn’s disease 2016-2020 against the ECCO-ESPGHAN recommendations
- P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study
- P606 Significant regional differences in referral patterns for bowel resection in Crohn’s disease patients
- P607 HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease
- P608 Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysis
- P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study
- P610 Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
- P611 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN’S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
- P612 Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study
- P613 Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort
- P614 Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort
- P615 The safety and efficacy of ustekinumab combined with sphincter-preserving surgery for perianal fistulizing Crohn’s disease:a single-center retrospective study
- P616 Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohort
- P617 Dual biologic therapy in pediatric Inflammatory Bowel Disease
- P618 Long-term real-world data of Ustekinumab in Ulcerative Colitis – the Stockholm Ustekinumab study – STOCUSTE
- P619 Inflammatory bowel disease meets fertility: a physicians and patients survey
- P620 Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?
- P621 Combination treatment of biologics with immunomodulator increases risk of infection after discharge in biologics naive steroid refractory acute severe ulcerative colitis patient: A KASID multicenter study
- P622 Change in Dietary Inflammatory Index Score in patients with Crohn’s disease and healthy volunteers following the Groningen Anti Inflammatory Diet (GrAID)
- P623 Mucosal eosinophils as markers of post-induction vedolizumab response in paediatric Ulcerative Colitis
- P624 Investigating the symptom burden among European patients with moderate-to-severe Crohn’s disease using a real-world survey
- P625 Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis
- P626 Safety of recombinant zoster vaccine in patients with Inflammatory Bowel Disease: a single centre experience
- P627 HLA DQA1*05 was not associated to primary non-response or loss of response to first anti-TNF in real world Inflammatory Bowel Disease patients.
- P628 Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
- P629 Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment
- P630 Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
- P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study
- P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy
- P633 Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costs
- P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
- P635 Risankizumab - real world Israeli data in severe refractory IBD patients
- P636 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease: Results from the EVOLVE Expansion study
- P637 Targeting mucosal healing: dose optimization of Vedolizumab in IBD patients with inadequate endoscopic response to standard dosing
- P638 Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study
- P639 Percutaneous drainage vs surgery as definitive treatment for anastomotic leak after intestinal resection in patients with Crohn’s disease.
- P640 Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases
- P641 Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patients
- P642 Network meta-analysis: efficacy and safety of treatments for fistulising Crohn’s disease
- P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study
- P644 Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate small intestinal mucosal healing in asymptomatic CRP-negative Crohn's disease
- P645 Use of Leukocytapheresis in inflammatory bowel disease in paediatric patients. A serie of 10 cases.
- P646 Relative association of bowel urgency clinically meaningful improvement and bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Work Productivity and Activity Impairment Scores in patients with m
- P647 Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience
- P648 Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.
- P649 Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease?
- P650 Integrin expression patterns of patients with IBD treated with vedolizumab.
- P651 Comparison of Adverse Events of SARS-CoV-2 Vaccination between Patients with Inflammatory Bowel Disease and Healthcare Workers
- P652 Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response.
- P653 Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn’s disease
- P654 Controversies in the management of anti-TNF therapy in Crohn’s disease patients. A Delphi consensus
- P655 MadCAM1 Negativity of Lamina Propria Endothelial Cells is Associated with Non-Response to Vedolizumab in Inflammatory Bowel Disease Patients
- P656 Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn’s disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
- P657 Current landscape of the real-world utilization of Interleukins 22, 23 and Interleukin 22 binding protein as biomarkers for Inflammatory Bowel Disease (IBD): A targeted literature review
- P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
- P659 Continuing or stopping 5-aminosalicylate in patients with Inflammatory Bowel Disease under anti-TNF therapy: A nationwide population-based study
- P660 Body composition and health-related quality of life in adult Crohn’s Disease during clinical remission: The INTICO2 cohort study
- P661 Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn’s disease: data from the ADVANCE and MOTIVATE studies
- P662 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease
- P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort
- P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
- P665 Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative Colitis
- P666 Effect of anastomotic configuration on Crohn’s Disease recurrence after primary ileocolic resection. A comparative monocentric study of end-to-end versus side-to-side anastomosis.
- P667 USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn’s Disease– results from STEADY study
- P668 Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResource
- P669 Improving Crohn’s disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammation
- P670 “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?
- P671 Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
- P672 Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
- P673 The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
- P674 Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
- P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
- P676 Intestinal ultrasound accurately predicts therapy failure in Crohn's disease patients during a biologics-induced remission
- P677 Combination of vedolizumab and exclusive enteral nutrition in patients with moderate to severe Crohn’s Disease
- P678 Ustekinumab therapy improves the nutritional status in patients with Crohn's Disease. A prospective study
- P679 Is the burden of obesity in IBD bigger than just weight?
- P680 A real-life experience of Crohn’s Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn’s disease
- P681 Effectiveness and safety of oral Tacrolimus salvage therapy for acute severe ulcerative colitis: a retrospective study
- P682 Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patients
- P683 Risk factors for fatigue in IBD patients.
- P684 Extra intravenous reinduction of ustekinumab on an already shortening interval is an effective optimisation strategy for patients with refractory Crohn’s disease
- P685 Early use of infliximab after seton technique for patients with Crohn’s disease who initially presented with perianal fistulas
- P687 Durability of recaptured response to ozanimod during the True North open-label extension
- P688 Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experiment
- P689 Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.
- P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
- P691 Disparate care: rates of treat to target among patients with inflammatory bowel disease
- P693 Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD study
- P694 Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrence
- P695 Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel Disease
- P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
- P697 De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
- P698 Role of an exclusion diet (reduced disaccharides, saturated fats, emulsifiers, red and ultraprocessed meats) in maintaining the remission of chronic inflammatory bowel diseases in adults
- P699 Ustekinumab therapy after biologic failure in patients with Crohn’s Disease – A real-world single centre experience
- P700 Perceptions towards established and emerging dietary therapies for Crohn’s disease management among the adult patients: results from a questionnaire survey
- P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval
- P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease
- P703 Real world experience of the transition from the intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: A review of current data
- P704 The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver disease
- P705 Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes
- P706 Monitoring asymptomatic patients with Crohn's disease: the role of intestinal ultrasound
- P707 Using urgent small bowel ultrasound (SBUS) as a tool for decision-making in patients with inflammatory bowel disease (IBD): retrospective analysis of United Kingdom (UK) patients' outcome.
- P708 Post-COVID-19 and Quality of Life in Patients with Immune Mediated Inflammatory Diseases
- P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine
- P710 Changes of gut microbiome after anti-TNF-α therapy and the prediction of clinical remission in patients with active ulcerative colitis
- P711 Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.
- P712 Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn’s Disease: Propensity Matched Analysis
- P713 Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel disease
- P714 Mucosal healing in CD with vedolizumab versus other biologics: endoscopic outcomes during long-term routine care in a multinational observational study
- P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study
- P716 A 2-week course of Exclusive Enteral Nutrition followed by the Crohn Disease Exclusion Diet is effective for Induction and Maintenance of Remission in children with Crohn Disease; the DIETOMICS-CD trial
- P717 Use of tramadol versus traditional opioids and adverse outcomes of Inflammatory Bowel Diseases: a Danish nationwide cohort study
- P718 A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn’s Disease
- P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment
- P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE
- P721 Treatment of Ulcerative Colitis with OSE-127 (lusvertikimab), a Strict IL-7Rα Antagonist, Non-Cytotoxic Monoclonal Antibody
- P722 Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapy
- P723 Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)
- P724 Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World Experience
- P725 Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates
- P726 Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trial
- P727 Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies
- P728 Real world evidence for adalimumab biosimilar, MSB 11022, therapy in inflammatory bowel diseases: Adherence analysis
- P729 Evaluation of hepatobiliary pathologies using transient elastography in patients with inflammatory bowel disease: What about the effect of drugs?
- P730 Anti tumor necrosis factor treatment in Ulcerative Colitis: Real-world data and evaluation of current treatment targets (STRIDE II)
- P731 Effect on direct and indirect costs of switching Inflammatory Bowel Disease patients from intravenous to subcutaneous infliximab (CT-P13)
- P732 Impact of different types of physical activity in inflammatory bowel disease
- P733 Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients
- P734 A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn’s disease prognosis - a prospective study
- P735 Real-life experience with the use of Tofacitinib in Colombian patients with moderate to severe Ulcerative Colitis: a descriptive study.
- P736 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial
- P737 Intensification with intravenous ustekinumab in refractory Crohn´s disease
- P738 Surgery for Crohn’s Disease: Results from a Spanish cohort with 15 years of follow-up
- P739 Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapy
- P740 Dual biologic therapy for patients with Inflammatory Bowel Disease in a single reference center in Spain
- P741 Do gastroenterology services need published standards for provision of antenatal care in patients with Inflammatory Bowel Disease? A local evaluation of UK practice.
- P742 Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: induction phase results from the prospective, observational RUN-UC study
- P743 Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active Ulcerative Colitis: An analysis from the LUCENT-1 and L
- P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
- P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
- P746 Identification of Altered Microbial Genera at Baseline in Adalimumab Clinical Remitters and an Absence of Change in Total Microbial Composition Post Induction Treatment in the SERENE UC Study
- P747 The impact of COVID-19 on patients with Inflammatory Bowel Disease: A population-based study using artificial intelligence.
- P748 Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)
- P749 Crohn’s disease stricture response and resolution with adalimumab therapy demonstrated with intestinal ultrasound. The STRIDENT randomised trial.
- P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease
- P751 Crohn’s Disease Exclusion Diet: A single centre real-life experience.
- P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
- P753 Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 months
- P754 Beyond Paneth cell metaplasia: Small intestinal metaplasia of the sigmoid colon in patients with Inflammatory Bowel Disease
- P755 Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETECCU (VACOVEII).
- P756 Cumulative adverse events of anti-TNF therapy in IBD patients at a large tertiary centre – a 13-year real-world experience
- P757 Visceral adiposity and not subcutaneous adiposity or body mass index is more strongly associated with relapse in inflammatory bowel disease
- P758 Impact of co-medication on rates of endoscopic remission: post-hoc analysis of randomised non-inferiority trial of 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
- P759 Perianal Crohn’s disease – therapeutic response and anal cancer risk - a single centre retrospective cohort
- P760 Adalimumab biosimilars versus Azathioprine: indirect comparison of efficacy, safety and persistence in treatment.
- P761 Negative Body Image in Inflammatory Bowel Disease persists despite Modern IBD care
- P762 Population Pharmacokinetic Model of Intravenous Infliximab in Korean Patients with Crohn’s Disease
- P763 Role of quality of life in patients with Inflammatory Bowel Disease
- P764 Effectiveness and safety of COVID-19 Vaccine among Patients with Inflammatory Bowel Disease: A medical center hospital-based study in central Taiwan
- P765 Tolerating infliximab therapeutic drug monitoring without anti-drug antibodies – an argument for drug intolerant assays?
- P766 Practical application of evidence-based dietary therapy into inflammatory bowel disease care shows high patient satisfaction, compliance, and efficacy. The Delectable Program
- P767 Intestinal ultrasonography predicts short term clinical remission in patients with moderate-to-severe ulcerative colitis
- P768 The prevalence and risk factors for malignancies in patients with inflammatory bowel disease in Crete : a case control study
- P769 Randomised feasibility study of preoperative medical nutrition therapy in adults undergoing surgery for Crohn’s disease
- P770 Autologous regulatory T cell transfer in patients with refractory ulcerative colitis: Interim report of a phase 1, dose-escalation trial
- P771 Biologics versus azathioprine in steroid-dependent ulcerative colitis: results from the A.U.R.O.R.A. database
- P772 Association of histological remission with long-term clinical outcomes in patients with ulcerative colitis: a multi-national retrospective study with centralized histological assessment
- P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment
- P774 Maintenance treatment with vedolizumab in children with Inflammatory Bowel Disease: follow-up results from the prospective multicenter VEDOKIDS study
- P775 Disease activity and treatment patterns of newly diagnosed adult patients with Crohn's disease in Japan: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD)
- P776 Polymeric exclusive enteral nutrition induces biochemical remission in adults with active Crohn’s Disease irrespective of disease location or concomitant steroid use
- P777 Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
- P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
- P779 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
- P780 Prognosis and optimal treatment for 5-aminosalicylic acid-intolerant patients with Ulcerative Colitis
- P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study
- P782 Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN)
- P783 Symptom Improvement of ulceRative colitis after an Injection dose of Ustekinumab in Japanese clinical practice, measured using patient-reported outcomes (SIRIUS) study, Interim Analysis
- P784 Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study
- P785 A retrospective cohort study on vedolizumab trough levels in Crohn’s disease patients
- P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease
- P787 Subcutaneous infliximab in IBD patients with previous immunogenic failure of intravenous infliximab
- P788 Endoscopic management of patients with high-risk colorectal colitis-associated neoplasia: a Delphi study
- P789 Inflammatory Bowel Disease subgroups identified by longitudinal faecal calprotectin profiles: A 10-year retrospective analysis of the Lothian IBD Registry
- P790 Examining mental health disease burden among Crohn’s Disease (CD) patients in Europe
- P791 Up to one third of rapid thiopurine-S-methyltransferase metabolizers manifest clinical and/or laboratory azathioprine side effects: A single centre experience
- P792 Pharmacokinetics and clinical evaluation of vedolizumab based on real-life routine monitoring data in IBD patients
- P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
- P794 Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
- P795 Impact of anxiety and depression on inflammatory bowel disease patients
- P796 Effectiveness and safety of ustekinumab for patients with ulcerative colitis: A single-centre retrospective study
- P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey
- P798 Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study.
- P799 Infliximab and immunomodulator combination therapy in inflammatory bowel disease – no longer inseparable?
- P800 Upadacitinib is effective and safe for Crohn’s Disease: prospective real-world experience
- P801 Maintenance phase effectiveness and persistence after two years in biologic-naïve ulcerative colitis patients treated with vedolizumab or anti-TNF (VEDO-IBD-study)
- P802 Relationships between validated clinical, endoscopic and histological indices in ulcerative colitis
- P803 Plasma N-glycan biomarkers predict patient Response to Vedolizumab treatment for Crohn’s Disease
- P804 Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance (GENIE)
- P805 Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative Colitis
- P806 Perianal Crohn’s Disease (pCD): The outcome of 2nd line and 3rd line biologics in perianal Crohn’s disease
- P807 Pregnancy and maternal outcomes in a cohort of patients with Inflammatory bowel disease: Encouraging data from a multi-disciplinary clinic in a tertiary center
- P808 Risk of relapse after vedolizumab withdrawal in Inflammatory Bowel Disease for patients in histological remission
- P809 The impact of different treatment strategies in newly diagnosed patients with Crohn’s Disease: a multicentre study
- P810 Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn’s Disease.
- P811 Combination biological or small molecule therapy in patients with refractory inflammatory bowel disease: a multicenter Brazilian experience
- P812 Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution in patients with inflammatory bowel disease
- P813 A scoping review on the assessment and improvement of health-related physical fitness in patients with Inflammatory Bowel Disease
- P814 Clinical trial design in Crohn’s disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2
- P815 Diet, nutrition, and the multidisciplinary approach in adults with Inflammatory Bowel Disease
- P816 The efficacy of an over the counter multivitamin and mineral supplement to prevent opportunistic infections in patients with inflammatory bowel disease in remission.
- P817 Symptoms of COVID-19 in Patients with Immune Mediated Inflammatory Diseases
- P818 Survival of ustekinumab treatment based on concomitant immunomodulator use
- P819 Histologic activity and clinical outcomes in Ulcerative Colitis
- P820 Comparison of three nutritional screening tools with the new GLIM criteria for malnutrition among definitive and elective surgery Crohn’s patients in China
- P821 Improving outcome after Inflammatory Bowel Disease surgery in an Enhanced Recovery After Surgery setting
- P822 The negative impact of mental health comorbidity in children and young adults with inflammatory bowel disease: a UK population-based cohort study
- P823 Biologic Penetration, hospitalization rates and need for major abdominal surgery in inflammatory bowel diseases: a comparative observational study between pediatric and adult patients
- P824 Sexual Dysfunction among young patients with Crohn´s disease. A Spanish case control study.
- P825 The course of inflammatory bowel disease in setting of liver transplantation
- P826 Economic impact of inflamatory bowel disease in Catalonia. A population-based analysis
- P827 SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with Inflammatory Bowel Disease: A systematic review and meta-analysis
- P828 Incidence and predictors of arterial and venous thromboembolic events in hospitalized patients with inflammatory bowel disease compared to patients with acute infective gastroenteritis and colitis: a propensity score-matched study.
- P829 The Burden of Colorectal Cancer in Patients with Ulcerative Colitis – Incidence and Risk factors from a Population-based Inception Cohort from Veszprem county, Western Hungary, from 1977–2020
- P830 Significant racial and ethnic disparities exist in health-care utilization in inflammatory bowel disease: a systematic review and meta-analysis
- P831 Clinical factors associated with severity in patients with Inflammatory Bowel Disease in Brazil (On Behalf of GEDIIB)
- P832 Cannabis Use in IBD Patients: A Population-Based Study
- P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study
- P834 Physical activity in people with Inflammatory Bowel Disease – towards precision prevention
- P835 Visceral adiposity independently predicts time to flare in inflammatory bowel disease, but BMI does not
- P836 Trends in the prevalence of Inflammatory Bowel Disease in Lithuania during 2001-2020
- P837 Incidence, evolution of disease phenotype, time to biological therapy and medium-, long-term surgery rates in IBD-U patients in Western Hungary – a population-based study between 1977–2020, data from the Veszprem county cohort
- P838 Increased Risk of Avascular Necrosis in Patients With Inflammatory Bowel Disease: a nationwide population based cohort study
- P839 Clinical activity in inflammatory bowel diseases is associated with consumption of processed foods
- P840 Longitudinal bidirectional association of physical activity and disease activity in children with Inflammatory Bowel Disease: a cohort study
- P841 Implication of Clostridioides difficile in the diagnosis and evolution of patients with pediatric inflammatory bowel disease.
- P842 SARS-CoV-2 antibody titers analysis in immune mediated inflammatory disease patients after COVID-19 vaccination: a monocentric retrospective study.
- P843 Mucinous and signet-ring colonic adenocarcinoma in Inflammatory Bowel Disease
- P844 Frequency of Extraintestinal Manifestations in vedolizumab versus anti-TNF Treated Patients with Inflammatory Bowel Diseases
- P845 Increased incidence of herpes zoster in patients with Inflammatory Bowel Diseases in Europe
- P846 Epidemiological and Clinical Characteristics of Inflammatory Bowel Diseases in Patients from Greece
- P847 Insomnia is common in IBD and associated with increased disability and abdominal pain
- P848 Risk of Orthorexia Nervosa in Patients with Inflammatory Bowel Disease: A Link with Eating Disorders?
- P849 Exposure to metals and minerals in hair samples of patients with preclinical inflammatory bowel disease
- P850 Co-medication before and after onset of inflammatory bowel disease in adults or elderly
- P851 Impact of an integrated model of care for inflammatory bowel disease on direct healthcare costs: A population-based matched cohort study from Saskatchewan, Canada
- P852 predictors of complicated disease course in UC in an administrative database: a nationwide study from the epi-IIRN
- P853 Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in the Faroe Islands compared to inflammatory bowel disease patients in Eastern and Western Europe – An Epi-IBD study
- P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1
- P855 The impact of the severe financial crisis on drug persistence and disease course in IBD patients in Lebanon
- P856 Associations of antibiotics, hormonal therapies, oral contraceptives, and long-term NSAIDs with Inflammatory Bowel Disease: results from the Prospective Urban Rural Epidemiology (PURE) study
- P858 Prevalence of sarcopenia in patients with inflammatory bowel disease and factors associated with it
- P859 Accuracy of self-reporting of immune-mediated inflammatory diseases by patients with inflammatory bowel disease. Results from a hospital-based cohort.
- P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings
- P861 Frequency and Influence of a Positive Family History on the Clinical Course of Inflammatory Bowel Diseases
- P862 Dietary risk factors associated with onset of IBD: a systematic literature review and meta-analysis
- P863 Exploring patients’ perceptions of clinical research in inflammatory bowel disease and barriers to participating in clinical trials
- P864 Frailty is associated with fatigue in older patients with Inflammatory Bowel Disease.
- P865 Anxiety and Depression is Associated with Poor Sleep Quality in patients with Inflammatory Bowel Disease (IBD)
- P866 Skin lesions among consecutive Inflammatory bowel disease patients in outpatient setting
- P867 Cost-effectiveness and cost-only studies for Inflammatory Bowel Disease surgery: a scoping review
- P868 Clinical features of chronic enteropathy associated with SLCO2A1 gene
- P869 Prevalence of Depression and Anxiety before and during the COVID-19 Pandemic in Puerto Ricans with Inflammatory Bowel Disease
- P870 What had the greatest impact on the quality of life of IBD patients on intravenous biological therapy in Montenegro during COVID-19?
- P871 Consideration of smoking and familial aggregation of appendectomy together may change our previous belief about the influence of appendectomy in Inflammatory Bowel Disease (Ulcerative Colitis vs Crohn's Disease).
- P872 Underrepresentation of Palestinian Citizens of Israel in Israeli Inflammatory Bowel Disease Trials
- P874 Comparison and Propensity Score of Seroconversion After Two Doses Of SARS-CoV-2 Vaccine in IBD Patients And Liver Transplant Recipients
- P875 Disease course of Ulcerative Colitis during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort
- P876 Disease course of Inflammatory Bowel Disease Unclassified in adult patients : a population-based study (1988-2014)
- P877 Risk of gastric cancer among patients with incident ulcerative colitis: A nationwide population based study.
- P878 Country is the main determinant of differences in nutritional therapy practices across Europe: Results of the Y-ECCO ClinCom Survey 2022
- P879 Clinical significance of plasma interleukin-22 as a biomarker of inflammation in patients with Crohn’s disease and ulcerative colitis
- P880 High incidence of inflammatory bowel disease in Northern Australia: a prospective community population-based Australian incidence study in the Mackay-Isaac-Whitsunday region
- P881 Is occupation a risk factor for developing Inflammatory Bowel Disease? A case-control study.
- P882 Regional differences in biologic and surgical treatment of inflammatory bowel disease in Norway 2011–2019
- P883 Parental and perinatal risk factors associated with onset of Inflammatory Bowel Disease: A systematic literature review and meta-analysis.
- P884 Association between psychosocial factors experienced in childhood or adolescence and occurrence of Inflammatory Bowel Disease (IBD) in adulthood: a case-control study in Quebec, Canada
- P885 Does long term corticosteroid use increase the risk of femur fracture in Inflammatory Bowel Disease patients? : A nationwide population-based cohort study
- P886 Clinical course and therapeutic management 5 years after diagnosis, in a cohort of Spanish patients with Crohn´s disease diagnosed in the 21st century.
- P887 Epidemiology of perianal fistulising Crohn’s disease: a systematic literature review
- P888 Evaluating patient access to infliximab subcutaneous in inflammatory bowel disease
- P889 Serologic response with antimicrobial antibodies during the preclinical phase of inflammatory bowel disease
- P890 Prevalence and Characteristics of Extra-intestinal Manifestations in a single cohort of Italian Patients with Inflammatory Bowel Disease
- P891 Estimating diet’s quality in patients with Crohn’s disease during remission
- P892 Characteristics and trend of Inflammatory Bowel Disease epidemiology for 30 years from 1991 to 2020: A single-center experience analysis in Incheon, Korea
- P893 Budget impact analysis of introducing infliximab subcutaneous for the treatment of Inflammatory Bowel Disease in Latvia
- P894 Diagnostic yield of routine stool pathogen tests during the relapse of Inflammatory Bowel Disease
- P895 Differences in ulcerative colitis patients regarding COVID-19 status
- P896 Inflammatory Bowel Disease in the elderly, a survey of elderly patient demographics, disease-related complications and compliance with vaccination and screening services
- P897 Longitudinal multi-tissue transcriptomic study reveals patient-specific drug response determinants in Inflammatory Bowel Disease patients.
- P898 Uncovering of tissue-associated risk factors that lead to different genetic risk profiles across Inflammatory Bowel Disease patients
- P899 Analysis of IL-23 receptor genetic variants associations with gut microbiome composition and barrier function in a cohort of healthy first-degree relatives of subjects with Crohn's disease
- P900 Studying causality association of ustekinumab with cardiovascular disease outcomes using Mendelian randomization
- P901 A genetic analysis of familial aggregation in Inflammatory Bowel Disease multiplex families
- P902 Native American Mapuche ancestry is related to higher IBD risk in Chileans
- P903 Lactase non-persistence and Inflammatory Bowel Disease in a Basque cohort
- P904 Genetic Variants in IBD Chilean Patients are related to clinical outcomes.
- P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry.
- P906 Prevalence and CARD9 IBD risk variant rs4077515 in a Chilean IBD Cohort.
- P907 NOD2 mutations are associated with the development of inflammatory and progressive digestive tract damage in Crohn’s disease
- P908 Faecal Microbiota Transplantation refurbishes the crypt-associated microbiota in Ulcerative colitis
- P909 Microbiome dynamics leading up to and during pregnancy in a matched IBD-control cohort
- P910 Emerging role of IL-33/ST2 and Gut Microbiota axis in the inflammatory process of ulcerative colitis patients with ileal pouch-anal anastomosis.
- P911 The changes in the faecal microbiome and metabolome in Crohn's disease after treatment with anti-TNFα antibodies are of secondary origin
- P912 Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease
- P913 Interactions between Intestinal Microbiota and micro-RNAs in Inflammatory Bowel Disease
- P914 An adult zebrafish model for adherent-invasive Escherichia coli indicates protection from infection by treatment with probiotic E. coli Nissle
- P915 Uncovering the role of Archaea in the pathogenesis of Inflammatory bowel disease
- P916 Small bowel permeability improvement is associated with microbial changes seen in mild to moderate active paediatric Crohn’s disease patients on nutritional therapy
- P917 Intestinal complement interacts with commensal microbiota and provides pattern recognition in Inflammatory Bowel Disease
- P918 Clostridium butyricum inhibits epithelial-mesenchymal transition of intestinal carcinogenesis through downregulating METTL3
- P919 Gut microbial signature and phenotype-specific Indicators in fecal microbiota of Korean patients with Inflammatory Bowel Disease
- P920 Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort
- P921 FMT in UC is associated with a decrease in Bacteroides-2 enterotype and response with baseline RNA and microbiota signatures
- P922 Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridium difficile infection
- P923 The pre-treatment gut microbiome at adult IBD inception: Initial signals from the Birmingham inception cohort
- P924 A unique gut microbiome signature can help differentiate Crohn`s Disease and isolated Terminal Ileitis
- P925 Deep functional assessment of the colonic mucosa-associated microbiota in Crohn's disease and health identifies pro- and anti- inflammatory secretomes and associated bacterial consortia. The ENIGMA study.
- P926 Blautia Obeum Aggravates Colitis in a Murine Model
- P927 Corticosteroid treatment in pediatric IBD patients reshapes the gut microbiota
- P928 Identification of mucosal microbiome-host gene interactions in ulcerative colitis patients
- P929 Gut mucosal microbiota composition in Inflammatory Bowel Disease introduced to infliximab
- N01 Using Item Response Theory to improve the efficiency of the Crohn and Colitis Knowledge score for patients with Inflammatory Bowel Disease
- N02 Our life is a roller-coaster! A qualitative phenomenological study exploring the impact of IBD on family members
- N03 Introducing video consultations as part of an IBD tight monitoring care pathway: interim results of the INTERACTION project
- N04 How to manage the concerns of patients with inflammatory bowel disease due to the transition from in-hospital to home management with oral or subcutaneous therapies: results of a survey of a cohort of patients in intravenous biologic treatment.
- N05 Highlighting the critical contributions of Inflammatory Bowel Disease nurses in Canada: Perspectives from nurses, gastroenterologists, individuals living with IBD, and caregivers.
- N06 The Introduction of Nurse Led Preconception and Pregnancy Education Clinics for patients with Inflammatory Bowel Disease
- N07 A qualitative study on how patients with Inflammatory Bowel Disease feel supported in managing their disease using an app
- N08 The emerging role of the IBD Care Manager: preliminary results from a survey by Italian IBD nurses
- N09 Exploration of medication adherence interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis: A Scoping Review of Randomised Controlled Trials.
- N10 Facilitators and inhibitors to first adult care visits in the transition from paediatric to adult orientated Inflammatory Bowel Disease healthcare
- N11 Adherence, self-care and illness perception in patients with Inflammatory Bowel Disease – a qualitative study.
- N12 Development and introduction of a pre-clinic screening, triage system and virtual consultations for patients with Inflammatory Bowel Disease: a nurse led quality improvement project (QIP)
- N13 Low compliance with remote monitoring of patient-reported outcomes via digital application in patients with inflammatory bowel disease
- N14 The satisfaction of IBD patients’ nursing care in biological therapy. Observational study
- N15 Influence of abundant nurse staffing on patient-reported outcomes among patients with inflammatory bowel disease in clinical remission
- N16 Exploring the factors that influence adjustment to and acceptance of an intestinal stoma for IBD: preliminary findings
- N17 Azathioprine - Is it really a dirty drug? IBD nurse's experience at Our Lady of Lourdes Hospital
- N18 Exploring the experiences of UK-dwelling Bangladeshi native language-speaking patients with Inflammatory Bowel Disease: preliminary findings from a qualitative study
- N19 Fear of not being accepted: a synthesis of qualitative experiences of children and adolescents living with IBD.
- N20 The added shame of IBD: experiences of people from various ethnic backgrounds discussing sexual wellbeing in clinical settings.
- N21 Patient education is (sometimes) better than cure.
- N22 Inflammatory bowel disease nursing in Italy: the experience of the Academic Hospital of Udine.
- N23 Burnout among European IBD specialists – a survey supported by ECCO
- N24 At Home Calprotectin a United Kingdom Patient Perspectives and Tertiary Center Experience
- N25 Diagnostic delay and economic burden in ibd: a multicenter italian experience in patients treated with biologics
- N26 Help-seeking experiences of patients with Inflammatory Bowel Disease from healthcare professionals: A qualitative descriptive study
- N27 Living well with IBD; An online survey from the UK
- N28 Satisfaction with telemedicine programs in inflammatory bowel disease: a natiowise multicenter study
- N29 Audit of Inflammatory Bowel Disease Telephone Advice Line
- N30 Understanding Inflammatory Bowel Disease Emergency Department Admissions in a Tertiary Referral Inflammatory Bowel Disease Centre in England: A quality Improvement project
- N31 Nothing about us, without us: Developing a reliable IBD information source on sexual well-being by patients and for patients